{"entity":{"id":"kernal-biologics","kind":"company","name":"Kernal Biologics","aka":[],"tldr":"Kernal Bio designs mRNA medicines that switch on only in the intended cell type, for example programming a patient's T cells against cancer inside the body without taking them out first.","summary":"Kernal Biologics develops cell-selective mRNA therapeutics: mRNA engineered to translate only in chosen cell types, delivered in lipid nanoparticles targeted to those cells. Its KR-402 programme uses T-cell-targeted particles to programme CAR-T cells in vivo and, per the company, achieves over 90 percent delivery efficiency with B-cell depletion within a week in preclinical models. Oncology applications include in vivo CAR-T and immune-stimulating mRNA for solid tumours. The company's YC profile names Hummingbird Ventures, Amgen Ventures, HBM and NASA among its backers; work is preclinical.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/kernal-biologics"},{"label":"Official website","url":"https://www.kernalbio.com"}],"tags":["yc"],"related":[],"cancers":[],"sections":["immunotherapy","cell-therapy"],"technologies":["in-vivo-car-t","neoantigen-mrna-vaccine"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.kernalbio.com","stage":"startup","ycBatch":"S20","investors":["y-combinator","amgen-ventures"],"funding":[]},"route":"/companies/kernal-biologics/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"amgen-ventures","kind":"company","name":"Amgen Ventures","route":"/companies/amgen-ventures/"},{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/"}]}}